Description
(AWP Alliance News) - Alcon acquired Neurotech Pharmaceuticals for USD 550 million, expanding its retina portfolio with ENCELTO, the only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2. Additional contingent payments may be required upon achievement of commercial milestones. ENCELTO received FDA approval in March 2025 and is currently available only in the U.S., where approximately 25,000 patients have been diagnosed with the disease.
The transaction is expected to be modestly accretive to net sales growth and slightly dilutive to core diluted EPS in 2027, becoming accretive thereafter.
https://www.businesswire.com/news/home/20261020151062/en/
Disclaimer: This news brief was created using generative artificial intelligence. Alcon AG published the original content used to generate this news brief via Business Wire on October 20, 2026, and is solely responsible for the information contained therein.
